Effectiveness and Safety of Anti-PCSK9 Treatment in Persons with Hyperlipidemia: A Register-Based Cohort Study

Keyphrases

• Register Study 100%
• Dyslipidemia 100%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 100%
• Alirocumab 100%
• Evolocumab 100%
• Low-density Lipoprotein Cholesterol Level 66%
• Cardiovascular Mortality 33%
• Denmark 33%
• Cardiovascular Disease 33%
• No Significant Difference 33%
• Treatment Initiation 33%
• Lipids 33%
• Major Adverse Cardiovascular Events 33%
• Therapeutic Solutions 33%
• Capital Region 33%
• Adverse Clinical Outcomes 33%
• Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cohort Study 100%
• Dyslipidemia 100%
• Hyperlipidemia 100%
• Proprotein Convertase 9 100%
• Alirocumab 100%
• Evolocumab 100%
• Low Density Lipoprotein Cholesterol 66%
• Cardiovascular Disease 33%

Immunology and Microbiology

• Alirocumab 100%
• Evolocumab 100%
• Low Density Lipoprotein Cholesterol Level 66%
• Solution and Solubility 33%